SCHEMBL10165374

SCHEMBL10165374

COc1ccc2ccn(CC(=O)C(C)(C)C)c2c1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MTNR1A P48039 6/20 0.57
MTNR1B P49286 6/20 0.57
HTR2A P28223 1/20 0.53
HTR2C P28335 1/20 0.53
TRPV1 Q8NER1 1/20 0.50
MCL1 Q07820 3/20 0.49
HDAC8 Q9BY41 2/20 0.47
ALDH1A1 P00352 2/20 0.47
HDAC3 O15379 1/20 0.47
HDAC4 P56524 1/20 0.47
HDAC1 Q13547 1/20 0.47
HDAC7 Q8WUI4 1/20 0.47
HDAC2 Q92769 1/20 0.47
HDAC10 Q969S8 1/20 0.47
HDAC11 Q96DB2 1/20 0.47
HDAC6 Q9UBN7 1/20 0.47
HDAC9 Q9UKV0 1/20 0.47
HDAC5 Q9UQL6 1/20 0.47
NCOR2 Q9Y618 1/20 0.47
HTR7 P34969 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10204441 0.88 MTNR1A (0.55) MTNR1AMTNR1BHTR2AHTR2CTRPV1
SCHEMBL10222047 0.84 MTNR1A (0.61) MTNR1AMTNR1BHTR2AHTR2CTRPV1
SCHEMBL16234635 0.84 MTNR1A (0.65) MTNR1AMTNR1BHTR2AHTR2CTRPV1
SCHEMBL6099343 0.83 MTNR1A (0.60) MTNR1AMTNR1BHTR2AHTR2CTRPV1
SCHEMBL11984620 0.82 MTNR1A (0.63) MTNR1AMTNR1BHTR2AHTR2CTRPV1
SCHEMBL10165545 0.80 KMO (0.57) MCL1ALDH1A1HTR7KDM4EPOLB
SCHEMBL10165565 0.78 GRIN2B (0.44) MTNR1AMTNR1BTRPV1MCL1ALDH1A1
SCHEMBL28661147 0.77 TFPI2 (0.52) MTNR1AMTNR1BHTR2AHTR2CTRPV1
SCHEMBL980885 0.76 HTR2C (0.65) MTNR1AMTNR1BHTR2AHTR2CTRPV1
SCHEMBL10165388 0.75 HTR2A (0.50) HTR2AHTR2CHDAC8HDAC3HDAC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8883766-B2 Ion channel modulators and methods of use VERTEX PHARMACEUTICALS INCORPORATED (US) 2014-11-11 US disclosed
US-20120208790-A1 ION CHANNEL MODULATORS AND METHODS OF USE VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-08-16 US disclosed
US-8193194-B2 Ion channel modulators and methods of use VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-06-05 US disclosed
US-8193194-B2 Ion channel modulators and methods of use VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-06-05 US disclosed
US-20080293737-A1 ION CHANNEL MODULATORS AND METHODS OF USE VERTEX PHARMACEUTICALS INCORPORATED 2008-11-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120208790-A1 ION CHANNEL MODULATORS AND METHODS OF USE CACNA1G, CACNA1C, CACNA1B MTNR1A 1851/4885MTNR1B 1385/4885HTR2A 720/4885
US-20080293737-A1 ION CHANNEL MODULATORS AND METHODS OF USE CACNA1G, CACNA1C, CACNA1B MTNR1A 1851/4885MTNR1B 1385/4885HTR2A 720/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.